LJAC
KPTI icon

L.J. Altfest & Co’s Karyopharm Therapeutics KPTI Stock Holding History

L.J. Altfest & Co’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-825
Closed -$128K – 268
2021
Q2 		$128K Buy
825
+11
+1% +$1.6K 0.03% 260
2021
Q1 		$128K Buy
+814
New +$172K 0.03% 267

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DMPV
Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

L.J. Altfest & Co's KPTI Position: Q3 2021 in Review

L.J. Altfest & Co sold out of Karyopharm Therapeutics (KPTI) in Q3 2021, closing a stake of 825 shares — an estimated $128K sold.

L.J. Altfest & Co first reported a position in KPTI in Q1 2021 and held it in 2 quarters. The position peaked at $128K in Q2 2021. 134 funds tracked by Wall St. Rank hold KPTI as of Q3 2021.

  • L.J. Altfest & Co reported no remaining Karyopharm Therapeutics position as of Q3 2021 after selling out during the quarter.
  • L.J. Altfest & Co sold 825 Karyopharm Therapeutics shares in Q3 2021, an estimated $128K.
  • L.J. Altfest & Co first reported a position in Karyopharm Therapeutics in Q1 2021 and held it in 2 quarters.
  • L.J. Altfest & Co's Karyopharm Therapeutics position peaked at $128K in Q2 2021.
  • 134 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2021.

Based on L.J. Altfest & Co's 13F filing for Q3 2021, filed 12 Oct 2021.